In the combined treatment of TB patients and MDR-TB patients coinfected with HIV, the risk of clinically significant drug-drug interactions increases, especially when considering the number of commonly coadministered anti-TB and antiretroviral medications that are either inducers or inhibitors of CYP, including newer anti-TB drugs such as bedaquiline and PA-824 (9, 10). Here, PPIG is linked to tuberculosis.